NCT06809179Phase 2Recruiting

A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder

Study sponsor: VistaGen Therapeutics, Inc. · VTGN

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-04Estimated

Enrollment · participants60Estimated

Source updated2026-02-05Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Social Anxiety Disorder

Treatments or interventions studied

Fasedienol Nasal Spray - Placebo Nasal SprayDrug
Fasedienol Nasal Spray - Fasedienol Nasal SprayDrug
Placebo Nasal Spray - Placebo Nasal SprayDrug

Primary outcomes · main study measures

measure: Subjective Units of Distress Scale (SUDS); description: The SUDS is a patient self-rated acute measurement scale that is scored in the range of 0 to 100 (operationalized for participants in this study as 0=totally relaxed or no anxiety at all and 100=highest distress or anxiety ever felt.; timeFrame: 7 days (Visit 2 to Visit 3)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history